Gastric Cancer:
DKN-01 + tislelizumab
+ chemotherapy
DKN-01 in gastric cancer
The expression of DKK1 is associated with shorter overall survival in gastric cancer patients and with shorter time to treatment progression on current therapies. DKN-01 has demonstrated significant tumor reductions in preclinical models and in clinical trials as a monotherapy and in combination with anti-PD-1 antibody immune checkpoint inhibitors and with chemotherapy.
Ongoing clinical trials in gastric cancer
P205 – DisTinGuish
The DisTinGuish study (NCT04363801) is a Phase 2 study of DKN-01 in combination with tislelizumab and standard of care (SOC) chemotherapy in patients with inoperable, locally advanced, G/GEJ adenocarcinoma. Part C of the DisTinGuish study will enroll approximately 160 first-line, HER2-negative patients. Patients will be randomized 1:1 to evaluate DKN-01 in combination with tislelizumab and standard of care (SOC) chemotherapy, compared to tislelizumab and SOC chemotherapy. The primary objective is progression-free survival (PFS) in DKK1-high patients. Secondary objectives of Part C include PFS in all patients regardless of DKK1 expression, as well as overall survival and objective response rate as measured by RECIST v1.1 in DKK1-high and all patients.
WaKING
The WaKING study (NCT04166721) is an investigator-sponsored study of DKN-01 in combination with atezolizumab, Roche’s anti-PD-L1 antibody, in patients with microsatellite stable esophagogastric cancer who have progressed following chemotherapy. This study is being sponsored by The Royal Marsden Hospital in the United Kingdom and being funded by Roche as part of its imCORE network.
Posters/manuscripts for the gastric cancer indication
Posters/manuscripts for the gastric cancer indication
- DisTinGuish: Tislelizumab combination: ASCO 2023 poster
- DisTinGuish: Tislelizumab combination: SITC 2022 poster
- DisTinGuish: Tislelizumab combination: ESMO 2022 poster
- WaKING: Atezolizumab combination: ESMO 2022 poster
- DisTinGuish: Tislelizumab combination: ESMO 2021 poster
- DisTinGuish: ASCO GI 2022 poster
- P102 Keytruda Combination Manuscript: Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers
- P102 Keytruda PD-1 Experienced Patients: SITC 2020
- P102 Keytruda Combination PD-1 Naïve Patients: ASCO GI 2020
- Paclitaxel combination: AACR 2018
- Esophageal Cancer Awareness Association